Meinian Onehealth(SZ:002044) Sou Hu Cai Jing·2026-01-16 06:14Group 1 - The AI healthcare concept in the A-share and Hong Kong markets is experiencing a "cooling" phase, with significant declines in stocks such as Alibaba Health and Weining Health [1][3] - The overall performance of the AH market has weakened, leading to a decrease in short-term sentiment and risk appetite among investors [3] - Despite short-term volatility, the long-term investment logic for AI healthcare remains intact, with the industry entering a critical phase of commercialization driven by national strategy and market demand [3] Group 2 - The global AI healthcare market is projected to grow from approximately $26.65 billion in 2024 to about $505.59 billion by 2033, with a compound annual growth rate (CAGR) of 38.8% [4] - In China, the AI healthcare industry is expected to increase from 97.3 billion yuan in 2023 to 159.8 billion yuan by 2028 [4] - The largest medical ETF in the market, with a scale of 27 billion yuan, covers 12 AI healthcare and brain-computer interface concept stocks, accounting for over 36% of its total weight [4]